73 results about "Depression model" patented technology

The invention discloses a construction method and application of a depression model. A drug capable of activating neurons in the lateral habenular nucleus brain area to discharge is given to the lateral habenular nucleus area of the brain of the experimental animal, and the depression model is obtained. The invention develops a new method for establishing the depression animal model by utilizing drug induction, local drug administration is performed on the brain of an experimental animal, abnormal discharge activity of neurons of lateral habenula nucleus (LHB) is activated, depression-like behaviors are generated, and the depression-like behaviors are induced to be more stable. Therefore, a new and reliable depression animal model is provided for researching the brain mechanism of depression and researching and developing novel drugs and non-drug intervention methods.

The invention discloses a composition for treating depression and application of the composition. The composition for treating depression is prepared from the following components in parts by weight: 35 to 40 parts of ligustilide, 0.5 to 1.5 parts of atractydin and 0.1 to 1 part of alpha-cyperone. According to the invention, the active components in the Yueju pill, which are targeted to 5-HT1AR and 5-HTT, are compounded for the first time to prepare a new traditional Chinese medicine functional component composition, and in addition, the anti-depression effect of the active components is evaluated by establishing a reserpine mouse depression model, so that the anti-depression effect of the Yueju pill is improved. The result shows that the active component composition screened by the 5-HT1AR and 5-HTT targets can adjust the content of monoamine neurotransmitters in brain tissues in vivo to achieve the anti-depression effect, and in-vivo pharmacological experiments fully prove that the composition has the anti-depression effect.

The invention provides lactobacillus plantarum for regulating mood health and resisting depression and application thereof, and the strain is separated from traditional pickles and is identified as lactobacillus plantarum. Experiments show that KY013 can significantly improve behavioral performance of depression model mice, and the effect of KY013 is equivalent to that of fluoxetine. The action mechanism comprises the following steps: up-regulating the levels of neurotransmitters such as 5-HT, DA, NE and GABA in hypothalamus, regulating the balance of proinflammatory factors (IL-6 and IFN-alpha) and anti-inflammatory factors (IL-10), and playing an anti-depression role through'neurotransmitter-immunity 'double ways. The KY013 disclosed by the invention can be used for developing antidepressant drugs or functional foods and the like, has the advantages of multi-target coordination, high safety and the like, and provides a new microecological preparation choice for treating depression.

The invention discloses application of a mitochondrial differentiation expression gene in preparation of a depression diagnostic agent and a depression treatment drug, and relates to the technical field of depression diagnosis and treatment. And the mitochondrial differentiation expression gene comprises one or more of TFAM (Transforming Factor Amplification Molecular), SURF1 and NDUFB9. According to the present invention, the SURF1 gene simultaneously expressed in inhibitory neurons and excitatory neurons is focused on, the key effect of the SURF1 in CUMS-induced depression-like behaviors is found, the CUMS-induced molecular and behavior changes are effectively reversed by the overexpression of the SURF1, and the potential anti-depression effect is displayed; besides, animal experiments find that overexpression of the SURF1 can effectively recover the function of an electron transport chain, ATP generation is enhanced, mitochondrial membrane potential is maintained, and oxidative stress is reduced. The effects jointly relieve depression-like behaviors induced by CUMS, and further support the protection effect of the SURF1 in a depression model, which provides evidence for the new effect of the SURF1 in the pathophysiology of depression.

The invention discloses application of traditional Chinese medicine monomer poplar bud flavin (including homologues thereof and extracts / mixtures containing the same) in preparation of drugs for treating nerve injury diseases and a preparation method of the drugs for treating the nerve injury diseases. The pharmacological action mechanism of the monomer poplar bud flavin is deeply explored, and animal model application effect verification proves that the monomer poplar bud flavin (including homologues thereof and extracts / mixtures containing the homologues) can obviously improve core symptoms of cerebral apoplexy, autism, Alzheimer's disease and depression models, is high in safety, and can be used for preparing a medicine for treating cerebral apoplexy, autism, Alzheimer's disease and depression models. The invention also develops a medicine for treating cerebral apoplexy, autism, Alzheimer's disease and depression, which takes the poplatin as a core component (including homologues of the poplatin and extracts / mixtures containing the poplatin), and is expected to provide new research results and application schemes for treatment of nerve injury diseases such as cerebral apoplexy, autism, Alzheimer's disease, depression and the like. The important significance is realized on improving the treatment effect.

The application provides an application of a motion-induced sweat extract in preparation of a medicine for treating, relieving or preventing depression and / or anxiety, and belongs to the field of biological medicine. Specifically, sweat is induced by making a healthy subject perform aerobic exercise of a specific intensity (such as 60%-80% of maximum heart rate), the sweat is collected and eluted by physiological saline, centrifuged and filtered to obtain a biologically active sweat extract. The extract is analyzed by transcriptomics and reverse transcription method to predict the anti-depression potential, and it is proved by in-vivo animal experiments that the extract can significantly improve the anhedonia, behavioral despair and anxiety-like behavior of a depression model mouse, and the effect of a high dose is equivalent to that of a first-line drug fluoxetine. The preparation raw material provided by the application is natural and safe, the preparation process is simple and the cost is low, and a new, easy-to-promote alternative strategy is provided for the prevention and treatment of depression.

The invention relates to the technical field of psychiatric pharmacology, discloses application of helicid in antidepressant drugs, and aims to solve the problems of large side effect, unstable curative effect, drug resistance and the like of existing antidepressant drugs. According to the medicine, through multiple mechanisms of activating a cAMP / PKA / CREB signal channel, promoting neuroplasticity, inhibiting neuronal apoptosis, relieving neuroinflammation and the like, the depressive symptom is remarkably improved. The preparation method comprises the steps of extraction and purification of helicid and preparation of the medicinal preparation. Animal experiments verify that the hilicidum-based antidepressant drug can effectively improve behavioral indexes of depression model rats, has low side effects, and does not have the problem of drug resistance. Compared with the traditional medicine, the medicine provided by the invention has the advantages that the treatment effect is improved, the adverse reaction is reduced, the application prospect is better, and a new medicine choice with a multi-target action mechanism is provided for the treatment of depression.

The invention discloses application of 4-isopropyltoluene to improvement of depression-like behaviors of mice. An experiment adopts a chronic constraint stress method to construct a depression model, through behavioral detection such as a sucrose preference test, a tail suspension test and a novel inhibition ingestion test, and in combination with molecular biology means such as immunofluorescent staining and Western blot, the anti-depression effect and potential mechanism of 4-isopropyltoluene are systematically evaluated, and the anti-depression effect and potential mechanism of 4-isopropyltoluene are evaluated. Results show that 4-isopropyltoluene plays a significant anti-depression role by inhibiting neuroinflammation, enhancing glial cell support function and activating AKT signal pathway, and has the potential of being developed into a novel anti-depression candidate drug.

The invention discloses a method for constructing a chronic heart failure co-disease depression animal model through composite intervention, and belongs to the technical field of disease animal model construction. Firstly, a left anterior descending coronary branch ligation operation is performed on a mouse to construct a heart failure model, and then a depression model is constructed by constraining mouse superposition. After composite modeling, the systolic function of the mouse is obviously reduced, the activity ability is weakened, and myocardial fibrosis and hippocampal tissue damage occur, which indicates that the heart failure co-disease depression model is successfully modeled. The animal model construction method has a good application prospect in research on the pathogenesis, biomarkers and treatment means of heart failure co-disease depression.

The invention relates to the technical field of biomedicine, in particular to an ELS-induced depression-like behavior rat whole-brain tissue lipid space metabolism analysis method which comprises the following steps: firstly, constructing an ELS-induced depression-like behavior rat model, and determining a depression model group by adopting a depression-like behavior test; then, taking a conventionally fed rat as a control group, respectively carrying out 2D scanning on the control group and the depression model group based on a mass spectrum space omics technology, constructing a 2D brain lipid map, and carrying out whole-brain 3D reconstruction to obtain brain tissue lipid mass spectrum imaging data; and finally, carrying out metabolic heterogeneity analysis on brain tissue lipid mass spectrum imaging data. The method provided by the invention aims to provide technical and data atlas support for research on a lipid metabolism disorder molecular mechanism of occurrence and development of early-stage negative stress induced depression from an animal model level, and meanwhile, the application range of a mass spectrum space omics technology is expanded.

The application discloses an application of NOD2 antagonist 1 in preparation of a medicine for preventing or treating depression, and belongs to the technical field of medicines. Specifically, the application relates to an application of a compound NOD2 antagonist 1 in preparation of a medicine for preventing or treating depression. The CAS registration number of the compound NOD2 antagonist 1 is 2411441-54-6. The application discloses a brand-new medicinal use of NOD2 antagonist 1, that is, the compound can be used for preparing a medicine for preventing or treating depression. Animal experiment results show that after intervention of NOD2 antagonist 1, the sucrose preference behavior of a depression model mouse is obviously improved, and depression-related emotional disorder performance is also obviously relieved. Based on the pharmacodynamic verification results, the technical scheme provided by the application has good clinical transformation and popularization and application prospects.

The invention provides a text-based gait depression detection method and device, equipment and a medium, and effectively solves the problem of low accuracy of an existing gait depression detection mode. The method comprises the following steps: extracting sample gait silhouette features from multiple frames of obtained sample gait silhouette images, and fusing the sample gait silhouette features and sample general text features to obtain sample gait text features; collecting sample scales with personalized answers replied by the plurality of sample detection objects to extract sample personalized text features; constructing an initial depression model based on the sample gait text features, and guiding the training of the initial depression model through the sample individual text features to obtain a depression model; and acquiring multiple frames of to-be-detected gait silhouette images of a target detection object during gait walking, and detecting the multiple frames of to-be-detected gait silhouette images based on the depression model to obtain a depression detection result of the target detection object.

The invention relates to application of broad bean pyrimidine in preparation of antidepressant drugs, and belongs to the technical field of biological medicines. Depression is a common and high-disability heavy mental disorder, has the core characteristics of remarkable and lasting emotion lowering and interest loss, seriously damages the social functions and life quality of patients, and has become one of the major public health burdens in the world. Based on new cognition of complex mechanisms of diseases, a new generation of antidepressant drugs which have a brand new action mechanism, can more accurately intervene in core pathological links of the diseases and can better meet the clinical requirements are researched and developed, and the new generation of antidepressant drugs are not only an inevitable direction for promoting psychopharmacology progress, but also are urgent medical necessities for improving prognosis of hundreds of millions of patients and relieving social burdens. A per2- / -mutant zebrafish depression model is used for performing drug screening on traditional Chinese medicine monomers, and finally it is found that 10 mM of broad bean pyrimidine has the anti-depression characteristic and can effectively improve the depression-like phenotype of per2- / -mutant zebrafish.

The invention relates to the technical field of medicines, and particularly provides application of a 6-(substituted pyridine-4-yl)-5-(substituted phenyl)-1, 2, 4-triazine compound derivative in preparation of an antidepressant drug. A cell experiment proves that the 6-(substituted pyridine-4-yl)-5-(substituted phenyl)-1, 2, 4-triazine compound is an antagonist of an adenosine 2A receptor, and a plurality of animal model experiments prove that the 6-(substituted pyridine-4-yl)-5-(substituted phenyl)-1, 2, 4-triazine compound has a relatively good treatment effect on a plurality of depression models. The compound has an application prospect of being used as an anti-depression treatment drug.

The invention provides a lipidosome preparation capable of performing brain-targeted drug delivery in a depression model, a preparation method of the lipidosome preparation and application of the lipidosome preparation in improving the anti-depression effect of fluoxetine, and belongs to the technical field of pharmaceutical preparations. The composition disclosed by the invention consists of DOPG, DSPE-PEG2000-PGP, DSPE-PEG2000, cholesterol, fluoxetine and celecoxib, and can be used for improving the anti-depression effect of fluoxetine. The double-drug-loading liposome with high entrapment efficiency and uniform particle size is prepared through a film hydration-film extrusion method, has good stability and biocompatibility, has an obvious targeting drug delivery effect in a chronic social contusion stress model, is suitable for a combined treatment strategy of depression, and has a good clinical application prospect.

The invention discloses a multi-wavelength laser mode adaptive switching method and system for a depression model, and relates to the technical field of laser adaptive switching. The multi-wavelength laser mode adaptive switching method and system for the depression model comprises the following steps: S1, constructing a multi-source stimulation data set, and performing quality marking and normalization processing; s2, constructing an equipment channel characteristic parameter set, and performing online correction and stability evaluation; s3, generating an equipment compensation stimulation sequence, and performing multi-wavelength laser mode adaptive switching and compensation; and S4, carrying out multi-source stimulation data full-link association and blood relationship management. According to the invention, the consistency of multi-wavelength laser stimulation output among multiple devices and the repeatability of depression model experiment conditions are effectively improved, and the problem that the physical output of the same stimulation scheme on different experiment devices is inconsistent is solved.

The present invention belongs to the technical field of traditional Chinese medicine, and in particular to a Chinese medicine composition for treating depression. The Chinese medicine composition is mainly prepared from astragalus, codonopsis, ophiopogon, polygonum multiflorum, epimedium, kudzu root, angelica, salvia miltiorrhiza, honeysuckle, seaweed, kelp, oyster, and immature bitter orange. The Chinese medicine composition of the present invention can significantly improve the symptoms of loss of appetite and weight loss in depression model rats, improve the symptoms of loss of interest in depression model rats, effectively alleviate the symptoms of increased inflammatory factors TNF-α, IL-1β, and INF-γ caused by depression, significantly increase the levels of 5-hydroxytryptamine and dopamine in rat cortex and hippocampus, and effectively treat depression.

The invention provides a method for verifying LA as a peripheral marker of depression, which comprises the following steps: step 1, collecting 11 plasma samples of juvenile depression patients meeting ICD-10 diagnostic standards before treatment and 11 healthy volunteer plasma samples of a juvenile control group, and detecting the LA content of peripheral plasma of each group; step 2, collecting plasma samples of 12 cases before treatment of adult depression patients conforming to ICD-10 diagnostic standards and plasma samples of 12 cases of healthy volunteers of an adult control group, and detecting the LA content of peripheral plasma of each group; 3, preparation of rats: 31 SD rats are selected; 4, a depression model rat is established through a CUMS method; 5, behavioral detection is conducted on the rats in the model group in the step 4, and finally 11 rats in the control group and 11 rats in the model group are obtained; and step 6, detecting the LA level in the peripheral blood of the model group rats and the control group rats. The invention proves that the LA can be used as an early-stage peripheral marker molecule for evaluating depression, and has important significance on psychiatric research and drug research and development.

The invention discloses a homogeneous polysaccharide from Xiaoyao powder as well as a preparation method and application of the homogeneous polysaccharide. The homogeneous polysaccharide is composed of arabinose, galactose, mannose, glucose and fructose, and the weight-average molecular weight Mw of the homogeneous polysaccharide is 293.223 kDa. The polysaccharide is separated and purified from Xiaoyao powder through water extraction, alcohol precipitation, ion exchange column chromatography, gel column chromatography and other preparation methods. Experimental results show that the homogeneous polysaccharide can improve cortisol-induced zebra fish depression model behavioral performance and improve exercise activity, has anti-depression activity, and can be used for preparing drugs for treating or preventing depression.

The invention relates to an anti-depression compound 4-methyl-6-methoxy coumarin, and belongs to the technical field of biological medicines. Depression is the most common mental disorder in the world and is also a main reason for disability. The development of a novel anti-depression drug which is based on a nerve plasticity mechanism, takes effect quickly, has a lasting curative effect and is high in safety, and particularly has important clinical requirements and technical necessity for an effective treatment means for refractory depression. Traditional Chinese medicine monomers and a per2- / -zebra fish depression model are adopted for anti-depression drug screening, and finally it is found that 10 mM of 4-methyl-6-methoxycoumarin has the anti-depression characteristic and has the positive treatment effect on the exploration behavior, social interaction and sleep-awakening period of per2- / -zebra fish. The method can effectively rescue and reverse depression-like phenotypes observed in a per2- / -zebra fish circadian rhythmic depression model, and can restore the balance of important gene expression.

The invention provides application of Turicibacter sanguinis in preparation of a medicine for preventing and / or treating depression, and belongs to the technical field of biological medicine. Researches find that compared with depression model mice, mice treated by T. sanguinis show significant behavior improvement: sucrose consumption is increased, retention time in an interaction area in a social interaction experiment (a CD1 mouse introduction stage) is prolonged, retention time and total movement distance in a central area in an open field experiment are both increased, and the mice treated by T. sanguinis show significant behavior improvement. And meanwhile, the standing time in a forced swimming experiment is shortened. The results of the behavioral test are consistent to show that the depression-like behavior of the mouse can be obviously alleviated by the T. sanguinis intervention.

The invention relates to the technical field of medicines, in particular to a composition for relieving depression, a preparation and application of the composition. The composition for relieving depression is prepared from the following components in parts by weight: 1 to 3 parts of nicotine and 100 to 5000 parts of imipramine. On a constructed mouse chronic unpredictable stress depression (CUMS) model, depression-like behavioral characteristics of model animals can be remarkably improved by intraperitoneal injection of low dose of nicotine and different doses of imipramine, and the effect is superior to that of a group singly using nicotine and a group singly using imipramine; the effect of rapidly relieving depression-like symptoms of animals can be achieved through the cooperation of low-dose nicotine and imipramine.

The invention relates to the technical field of medicines, in particular to application of artemisia vulgaris in preparation of an anti-depression medicine. According to the application disclosed by the invention, the depression is systematically researched through a chronic depression model induced by chronic unpredictable mild stress (CUMS) and an acute depression model induced by lipopolysaccharide (LPS). Experimental results show that under the stimulation of CUMS or LPS, experimental animals show obvious depression-like behaviors. Compared with a negative control group, depression-like behaviors of mice in the CUMS model group and the LPS model group are confirmed, and behavior abnormalities induced by the two models can be effectively improved after intervention of the artemisinin. Further comparative research finds that the antidepressant effect of the clinically common antidepressant drug venlafaxine with the dosage of 10 mg / kg can be achieved under the dosage of 1 mg / kg of the artemisinin, and the artemisinin has remarkable antidepressant activity. The application has a good application prospect when being applied to the development of anti-depression drugs.

The invention discloses a research method for improving depression by influence of movement on hippocampus, and relates to the field of medical science. Comprising the following steps: grouping experimental animals and constructing a model, selecting animal groups, and establishing a CUMS depression model; performing swimming exercise intervention, setting training parameters, and performing intervention by using an inhibitor; sample collection and molecular detection: anesthetizing animals, taking hippocampus tissues, and carrying out ferroptosis index detection, protein and gene expression analysis and neuron morphology observation on the hippocampus tissues; data analysis and mechanism verification are carried out, and behavioristics and molecular index correlation analysis and path blocking experiments are carried out respectively. According to the invention, the ferroptosis mechanism is associated with the motion anti-depression effect for the first time, the hub effect of the Nrf2 / SLC7A11 / GPX4 pathway is disclosed, behavioristics, molecular biology and ultrastructure analysis are integrated, a multi-dimensional verification system is established, quantifiable motion intervention parameters are provided, and a basis is provided for formulating a clinical motion prescription.

The application belongs to the technical field of biological medicine, and relates to a drug for treating depression, and in particular to application of cyclopentolate combined with esketamine in preparation of a drug for treating depression. Experimental researches of the application show that, compared with cyclopentolate or esketamine alone, cyclopentolate combined with esketamine can more significantly improve the depressive behavior of CRS depressive model mice, and it is proved that cyclopentolate combined with esketamine can synergistically enhance the anti-depression effect, so as to be used as a drug for treating depression.

The invention discloses application of allyl isothiocyanate in preparation of drugs or health-care foods for improving mental disorder, and belongs to the technical field of medicines. Allyl isothiocyanate shows rapid, convenient and efficient intervention potential for depression, emotional disorder, social difficulty, biphasic emotional fluctuation, anxiety and autism spectrum symptoms when used as a functional component of a medicine or health food. Specific experiments verify that in a depression model constructed by adopting social contusion stress, the component can obviously reverse typical depression-like behaviors such as social avoidance tendency and behavioral despair states shown by mice. In a chronic unpredictable stress induced model, allyl isothiocyanate effectively relieves anxiety and depression symptoms of mice and recovers pleasant sensation experience ability of the mice. In a drug-induced bipolar affective disorder model, the component obviously stabilizes the manic attack and depression alternating behavior of mice. In an autism model mouse, the allyl isothiocyanate effectively relieves the repetitive engraving behavior of the autism model mouse.

The invention relates to application of 4 '-demethyl epipodophyllotoxin or a medicinal derivative thereof in depression resistance, and belongs to the technical field of biological medicines. Depression is a serious nervous and mental disease and affects millions of people in the world. Major depression is the most common mental disorder and is also one of the main causes of global disability. Depression is considered to be a complex disease caused by interaction of genetic, physiological, psychological and environmental factors. It is found that the novel antidepressant drug capable of treating depression has great significance. A per2- / -mutant zebrafish depression model is utilized to perform drug screening on traditional Chinese medicine monomers, and finally, 10 mu M of 4 '-demethylepipodophyllotoxin has an anti-depression characteristic and can effectively improve the depression-like phenotype of per2- / -mutant zebrafish. A medicinal plant podophyllotoxin from which 4 '-demethyl epipodophyllotoxin is extracted is safe and non-toxic, and no report about 4'-demethyl epipodophyllotoxin depression resistance exists at present.

The invention discloses lactobacillus reuteri FMZ07 and application thereof in depression resistance and intestinal flora improvement, and belongs to the technical field of biomedicine. The strain is preserved in the China General Microbiological Culture Collection Center (CGMCC for short), the preservation address is Institute of Microbiology, Chinese Academy of Sciences, No.3, No.1 Yard, Beichen West Road, Chaoyang District, Beijing, the preservation number is CGMCC No.37751, the preservation date is February 9, 2026, and the strain is named as Lactobacillus reuteri in taxonomy. The strain can regulate'microorganism-intestine-brain axis' through multiple targets, the depression-like behavior of depression model mice is remarkably improved, meanwhile, the richness and uniformity of intestinal flora are recovered, and reliable microorganism resources are provided for developing probiotic preparations or drugs for improving depression and assisting improvement of intestinal flora.

The invention discloses an anti-depression plant extract which is prepared from a ginseng extract, a rhizoma acori graminei extract, a polygala tenuifolia extract, a poria with hostwood extract, a dragon bone extract and an oyster extract. The formula comprises the following components in percentage by weight: 9.81% of a ginseng extract, 58.86% of a rhizoma acori graminei extract, 9.25% of a polygala tenuifolia extract, 12.26% of a poria with hostwood extract, 4.90% of a fossil fragments extract and 4.90% of an oyster extract. The concentration of the formula is 0.4 mu g / mL-1. 6 mu g / mL, preferably 0.8 mu g / mL. The invention relates to the technical field of anti-depression extracts. The anti-depression plant extract has obvious neuroprotection, anti-inflammation and neurotransmitter regulation effects by adopting total ginsenoside, has an anti-depression effect, effectively improves the depression state of a depression model rat by adopting beta-asarone, and has the anti-depression effect mainly by protecting hippocampal nerve synaptic plasticity and inhibiting neuroinflammation. Therefore, the rhizoma acori graminei extract has an anti-depression effect.

The invention belongs to the technical field of biological medicine, and particularly discloses application of secoxyloganin in preparation of an antidepressant drug, and the antidepressant drug further contains a pharmaceutically acceptable carrier. The antidepressant drug is one of an oral preparation, an inhalant and an injection; the oral preparation is one of a suspending agent, an emulsion, a solution, powder, tablets, granules and capsules. When the secoxyloganin is used as the effective component of the antidepressant drug, the depression-like behavior of a depression model mouse induced by LPS (Lipopolysaccharide) can be effectively improved.